Loading
Life sciences · Journal article
Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Late-onset hypogonadism (LOH), also termed age-related testosterone deficiency, is a clinical and biochemical syndrome affecting aging men. It is characterized by persistent hypogonadal symptoms paired with low serum testosterone levels. Unlike classical organic hypogonadism, LOH stems from a complex multifactorial mechanism involving age-related Leydig cell senescence, altered hypothalamic-pituitary-testicular (HPT) axis feedback, increased sex hormone-binding globulin (SHBG) levels, and reciprocal metabolic crosstalk driven by visceral obesity. Diagnosis requires a strict two-step protocol: identification of key clinical manifestations—predominantly core sexual symptoms such as decreased morning erections, erectile dysfunction, and low libido—and confirmation through two separate fasting morning serum total testosterone draws (typically < 300 ng/dL or 10.4 nmol/L). In borderline cases, calculated free testosterone (< 6.5 ng/dL) is decisive. Left untreated, LOH acts as an accelerator of multi-system physiological decline, compounding sarcopenia, osteopenia, metabolic syndrome, type 2 diabetes, and cardiovascular risk, thereby reducing functional independence and overall quality of life. Management begins with non-pharmacological lifestyle interventions, particularly weight loss and resistance training, which can restore endogenous testosterone in functional/obesity-related cases. For persistent hypogonadism, exogenous testosterone replacement therapy (TRT)—delivered via transdermal gels, intramuscular injections, or subcutaneous pellets—provides effective symptomatic relief. In men desiring preserved fertility, alternative agents such as selective estrogen receptor modulators (SERMs) or human chorionic gonadotropin (hCG) are preferred to prevent HPT axis suppression. Landmark clinical trials, such as the TRAVERSE study, confirm the cardiovascular safety (non-inferiority for major adverse cardiovascular events) of TRT in high-risk populations while highlighting the necessity of ongoing safety monitoring for erythrocytosis (hematocrit > 54%), prostate-specific antigen (PSA) elevations, and atrial fibrillation. Overall, structured diagnosis and tailored therapy allow clinicians to mitigate age-related frailties and promote healthy aging. [J Assoc Clin Endocrinol Diabetol Bangladesh, 2026;5(Suppl 1): S12]